drugset / Trial / NCT00533676

Endpoint Validation Study (0524A-015)

NCT00533676

Phase 2 Completed 165 enrolled Merck Sharp & Dohme LLC
RandomizedParallel-groupDouble-blindTreatment

Summary

To determine the most effective daily dose of MK0524A when compared with placebo after the 8-week treatment period for Niacin Induce Flushing (NIF).

Timeline

Start
2004-08
Primary completion
2006-12
Completion
2006-12

Drugs

EvaluationDrugModalityDoseRoute
Subject MK0524A Unknown